Compare ORGO & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORGO | TTRX |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.3M | 281.2M |
| IPO Year | 2016 | 2025 |
| Metric | ORGO | TTRX |
|---|---|---|
| Price | $1.81 | $9.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $8.50 | $8.00 |
| AVG Volume (30 Days) | ★ 878.3K | 70.7K |
| Earning Date | 05-07-2026 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1600.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $564,169,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $26.27 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 17.04 | N/A |
| 52 Week Low | $1.54 | $2.57 |
| 52 Week High | $7.08 | $11.69 |
| Indicator | ORGO | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 28.03 | 56.29 |
| Support Level | $1.54 | $2.95 |
| Resistance Level | $2.64 | $10.48 |
| Average True Range (ATR) | 0.13 | 0.85 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 23.00 | 68.38 |
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.